Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. [electronic resource]
Producer: 20180129Description: 921-5 p. digitalISSN:- 1477-0970
- Adult
- Female
- Humans
- Immunosuppressive Agents -- adverse effects
- Leukocyte Count
- Lymphocytosis -- blood
- Magnetic Resonance Imaging
- Male
- Multiple Sclerosis, Chronic Progressive -- blood
- Multiple Sclerosis, Relapsing-Remitting -- blood
- Natalizumab -- adverse effects
- Predictive Value of Tests
- Retrospective Studies
- Risk Factors
- Time Factors
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.